Novartis Ag

Darren Mark Le Grand

Judy Fox Hayler

Ian Bruce

Clive McCarthy

Yves Auberson

Gurdip Bhalay

Emma Budd

Christopher Thomson

Berndt Oberhauser

Emmanuelle Briard

Clive Victor Walker

Trevor John Howe

Keith Allan Menear

Stephen Paul Collingwood

Catherine Howsham

David Andrew Sandham

Urs Baettig

Lee Edwards

Bernard Cuenoud

Kamlesh Jagdis Bala

David Beattie

Xiao-Ling Fan Cockcroft

Catherine LeBlanc

Jeffrey McKenna

Graham Charles Bloomfield

Henri Mattes

Katrin Spiegel

Thomas Hugo Keller

Glyn Alan Hughes

Thomas Storz

Vikki Furminger

Emily Stanley

Nicola Press

Cathy Ritchie

Gaynor Elizabeth Pilgrim

Andrew Stuart Lister

Barbara Valade

David William Pearce

Oliver Ross Steward

Owen Rhys Hughes

John James Woods

The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

Pyridine and pyrazine derivative for the treatment of chronic bronchitis

Preparation of novel 2-benzyl-5-methyl-2H-tetrazole derivatives of the formula (I) for use as PET imaging agents. The present invention relates to novel compounds of formula (I) their preparation and use as PET imaging agents for imaging techniques and diagnostics in the field of diseases and disorders mediated by or related to the enzyme autotaxin. 

Pet imaging agents

PET Imaging agents

The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.

Autotaxin inhibitors

The present invention relates to novel compounds of formula (I) (I) that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in the treatment of an ATX-dependent or ATX-mediated disease or condition. 

Compounds of formula I in free or salt form, wherein R, R, Rand Rhave the meanings as indicated in the specification, are useful for treating conditions that are mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

Inhibitors of phosphatidylinositol 3-kinase

in free or salt form, wherein R, R, R, R, Rand Rhave the meanings as indicated in the specification, are useful for treating conditions that are mediated by mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylin ositol 3 kinase enzymes (PI13) for treatment of inflammatory diseases

Compounds of formula I in free or salt form, wherein Ar, X, Y, R, R, R, R, m, n, p and q have the meanings as indicated in the specification, are useful for treating conditions mediated by CCR3. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Azetidine derivatives as CCR-3 receptor antagonists

Compounds of formula (I) in free or salt form, where Aris phenyl substituted by one or more substituents selected from halogen, cyano, nitro, and C&#x2013;C-alkyl optionally substituted by cyano or halogen, Aris phenyl optionally which is unsubstituted or substituted by one or more substituents selected from halogen, cyano, hydroxy, nitro, C&#x2013;C-alkyl, C&#x2013;C-haloalkyl, C&#x2013;C-alkoxy or C&#x2013;C-alkoxycarbonyl, Ris C&#x2013;C-alkyl substituted by hydroxy, C&#x2013;C-alkoxy, acyloxy, &#x2014;N(R)R, halogen, carboxy, C&#x2013;C-alkoxycarbonyl, phenyl-C&#x2013;C-alkoxycarbonyl, &#x2014;CON(R)Ror by a monovalent cyclic organic group, Rand R?3are each independently hydrogen or C&#x2013;C-alkyl, or Ris hydrogen and Ris acyl or SOR, or Rand Rtogether with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclic group, Rand Rare each independently hydrogen, C&#x2013;C-alkyl optionally substituted by hydroxy or phenyl, or phenyl optionally substituted by C&#x2013;C-alkyl, halogen, cyano or C&#x2013;C-alkoxy, or Rand Rtogether with the nitrogen atom to which they are attached denote a 5- or 6-membered heterocyclic group, R?6is C&#x2013;C-alkyl, C&#x2013;C-haloalkyl, or phenyl optionally substituted by C&#x2013;C-alkyl, and n is 1, 2, 3 or 4. The compounds are useful as pharmaceuticals.

N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as CCR33 receptor antagonists

Piperidine compounds for use as ccr-3 inhibitors

Purine derivatives inhibitors of tyrosine protein kinase SYK

Growing community of inventors

Horsham, United Kingdom

Darren Mark Le Grand